Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

BEIJING and BRIDGEWATER,N.J.,Dec. 18,2024--Gan & Lee Pharmaceuticals (Gan & Lee,Shanghai Stock Exchange: 603087.SH),is pleased to announce that the Food and Drug Administration (" FDA &q